Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Therapix Bio Signs MOU with Nanjing BioSciKin for Antibody

publication date: Dec 24, 2014
Therapix Biosciences , an Israeli biotech accelerator, announced a MOU to out-license China rights for its anti-CD3 antibody to Nanjing BioSciKin. As it currently stands, the agreement calls for BioSciKin to be responsible for all China development costs of the antibody plus build a GMP-compliant manufacturing line. BioSciKin will pay $300,000 upfront. Once BioSciKin takes over, Therapix intends to turn its attention to the synthetic cannabinoid drugs being developed by Lara Pharma, a company in which it owns a 25% stake. More details....

Stock Symbols: (TASE: TRPX; OTCQB: THXBY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital